{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:59:22Z","timestamp":1790564362675,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In axial spondyloarthritis (axSpA), 5\u201310% of patients have comorbid inflammatory bowel disease (IBD). Beyond that, 50\u201360% display histologic inflammation in ileum\/colon biopsies, and fecal calprotectin (F-calprotectin) is elevated in relation to healthy controls. Prior studies have shown such, often subclinical, gut inflammation in axSpA to be associated with more active disease, as measured by clinical indices as well as magnetic resonance imaging \u2013 both known risk factors for structural spinal damage development. In light of this, in the current study we aimed to examine whether gut inflammation, assessed by F-calprotectin, is associated with more structural spinal damage in axSpA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with well-characterized non-radiographic or radiographic axSpA (nr-axSpA\/r-axSpA;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200976\/152), according to ASAS or modified New York criteria, enrolled in a population-based cohort study in southern Sweden, were assessed for structural spinal damage (modified Stoke ankylosing spondylitis spinal score [mSASSS]) and gut inflammation (F-calprotectin). mSASSS values were compared between patients with normal (&lt;\u200950\u00a0mg\/kg), moderately elevated (50\u2013149\u00a0mg\/kg) or distinctly elevated (\u2265\u2009150\u00a0mg\/kg) F-calprotectin, reflecting no\/some\/evident gut inflammation, respectively (one-way ANOVA). Moreover, logistic regression was applied to explore if elevated F-calprotectin (\u2265\u200950\u00a0mg\/kg) was associated with mSASSS values above the median, adjusted for sex, symptom duration, HLA-B27 status, smoking, CRP, NSAID and anti-TNF therapy. Analyses limited to r-axSpA were also performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In both axSpA patients overall and separately in r-axSpA, mSASSS distributions differed significantly between subjects with normal\/moderately\/distinctly elevated F-calprotectin, with more damage observed in those with higher F-calprotectin levels. Furthermore, elevated F-calprotectin (\u2265\u200950\u00a0mg\/kg) was associated with mSASSS values above the median, in both the entire axSpA group (adjusted odds ratio [OR] 2.2 [95%CI 1.1\u20134.2]); and in r-axSpA alone (adjusted OR 2.9 [1.2\u20137.1]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the current study, the presence of gut inflammation, assessed by F-calprotectin, was cross-sectionally associated with more structural damage in the spine in patients with axSpA, even after adjustments for known risk factors for spinal damage. Prospective studies are, however, needed to investigate whether gut inflammation may be a predictor of spinal radiographic progression in axSpA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-025-03663-z","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:27:04Z","timestamp":1761035224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Gut inflammation is associated with structural spinal damage in axial spondyloarthritis \u2013 results from the observational SPARTAKUS cohort"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4915-2924","authenticated-orcid":false,"given":"Johan Karlsson","family":"Wallman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5706-203X","authenticated-orcid":false,"given":"Elisabeth","family":"Mogard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-0665","authenticated-orcid":false,"given":"Jonas","family":"Sagard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7021-2541","authenticated-orcid":false,"given":"Kristofer","family":"Andr\u00e9asson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4808-0014","authenticated-orcid":false,"given":"Jan","family":"Marsal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8629-588X","authenticated-orcid":false,"given":"Fatih","family":"Inci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0529-7723","authenticated-orcid":false,"given":"Mats","family":"Geijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-4487","authenticated-orcid":false,"given":"Tor","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-6352","authenticated-orcid":false,"given":"Elisabet","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"3663_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0016-5085(89)91557-6","volume":"96","author":"M De Vos","year":"1989","unstructured":"De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology. 1989;96:339\u201344.","journal-title":"Gastroenterology"},{"key":"3663_CR2","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","volume":"72","author":"L Van Praet","year":"2013","unstructured":"Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72:414\u20137.","journal-title":"Ann Rheum Dis"},{"key":"3663_CR3","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/1756-185X.14388","volume":"25","author":"JF Campos","year":"2022","unstructured":"Campos JF, Resende GG, Barbosa AJA, de Carvalho SC, Lage JA, Cunha PFS, et al. Fecal calprotectin as a biomarker of microscopic bowel inflammation in patients with spondyloarthritis. Int J Rheum Dis. 2022;25:1078\u201386.","journal-title":"Int J Rheum Dis"},{"key":"3663_CR4","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.3310\/hta17550","volume":"17","author":"N Waugh","year":"2013","unstructured":"Waugh N, Cummins E, Royle P, Kandala NB, Shyangdan D, Arasaradnam R, et al. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation. Health Technol Assess. 2013;17:xv\u2013xix.","journal-title":"Health Technol Assess"},{"key":"3663_CR5","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/rheumatology\/key427","volume":"58","author":"T Olofsson","year":"2019","unstructured":"Olofsson T, Lindqvist E, Mogard E, Andreasson K, Marsal J, Geijer M, et al. Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort. Rheumatology (Oxford). 2019;58:1176\u201387.","journal-title":"Rheumatology (Oxford)"},{"key":"3663_CR6","first-page":"71","volume":"16","author":"A Duran","year":"2016","unstructured":"Duran A, Kobak S, Sen N, Aktakka S, Atabay T, Orman M. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Bosn J Basic Med Sci. 2016;16:71\u20134.","journal-title":"Bosn J Basic Med Sci"},{"key":"3663_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19\u201334.","journal-title":"Ann Rheum Dis"},{"key":"3663_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2018.1477591","volume":"14","author":"M Protopopov","year":"2018","unstructured":"Protopopov M, Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol. 2018;14:525\u201333.","journal-title":"Expert Rev Clin Immunol"},{"key":"3663_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11926-018-0795-4","volume":"20","author":"I Sari","year":"2018","unstructured":"Sari I, Haroon N. Radiographic progression in ankylosing spondylitis: from prognostication to disease modification. Curr Rheumatol Rep. 2018;20:82.","journal-title":"Curr Rheumatol Rep"},{"key":"3663_CR10","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1002\/art.24024","volume":"58","author":"AN Bennett","year":"2008","unstructured":"Bennett AN, McGonagle D, O\u2019Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum. 2008;58:3413\u20138.","journal-title":"Arthritis Rheum"},{"key":"3663_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73:1455\u201361.","journal-title":"Ann Rheum Dis"},{"key":"3663_CR12","first-page":"42","volume":"115","author":"J Simioni","year":"2023","unstructured":"Simioni J, Skare T, Ioshii S, Campos A, Longo B, Messias-Reason I, et al. Intestinal histological findings in patients with spondyloarthritis: a study of the relationship with disease activity. Rev Esp Enferm Dig. 2023;115:42\u20133.","journal-title":"Rev Esp Enferm Dig"},{"key":"3663_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13075-017-1223-2","volume":"19","author":"E Klingberg","year":"2017","unstructured":"Klingberg E, Strid H, Stahl A, Deminger A, Carlsten H, Ohman L, et al. A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis. Arthritis Res Ther. 2017;19:21.","journal-title":"Arthritis Res Ther"},{"key":"3663_CR14","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2013-203854","volume":"73","author":"L Van Praet","year":"2014","unstructured":"Van Praet L, Jans L, Carron P, Jacques P, Glorieus E, Colman R, et al. Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort. Ann Rheum Dis. 2014;73:1186\u20139.","journal-title":"Ann Rheum Dis"},{"key":"3663_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/03009742.2017.1299216","volume":"47","author":"RD Ostgard","year":"2018","unstructured":"Ostgard RD, Deleuran BW, Dam MY, Hansen IT, Jurik AG, Glerup H. Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis. Scand J Rheumatol. 2018;47:48\u201355.","journal-title":"Scand J Rheumatol"},{"key":"3663_CR16","unstructured":"CALPRO, The Calprotectin Company. https:\/\/www.calpro.no. Accessed 25 August 2025."},{"key":"3663_CR17","doi-asserted-by":"publisher","first-page":"e00617","DOI":"10.14309\/ctg.0000000000000617","volume":"14","author":"N Kapel","year":"2023","unstructured":"Kapel N, Ouni H, Benahmed NA, Barbot-Trystram L. Fecal calprotectin for the diagnosis and management of inflammatory bowel diseases. Clin Transl Gastroenterol. 2023;14:e00617.","journal-title":"Clin Transl Gastroenterol"},{"key":"3663_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15:155\u201363.","journal-title":"J Chiropr Med"},{"key":"3663_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","volume":"13","author":"HS de Souza","year":"2016","unstructured":"de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13\u201327.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3663_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13075-022-02853-3","volume":"24","author":"PR Sternes","year":"2022","unstructured":"Sternes PR, Brett L, Phipps J, Ciccia F, Kenna T, de Guzman E, et al. Distinctive gut microbiomes of ankylosing spondylitis and inflammatory bowel disease patients suggest differing roles in pathogenesis and correlate with disease activity. Arthritis Res Ther. 2022;24:163.","journal-title":"Arthritis Res Ther"},{"key":"3663_CR21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/annrheumdis-2019-216134","volume":"79","author":"JK Wallman","year":"2020","unstructured":"Wallman JK, Mogard E, Marsal J, Andreasson K, J\u00f6ud A, Geijer M, et al. Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity? Ann Rheum Dis. 2020;79:159\u201361.","journal-title":"Ann Rheum Dis"},{"key":"3663_CR22","doi-asserted-by":"publisher","first-page":"650619","DOI":"10.3389\/fmed.2021.650619","volume":"8","author":"L Lamot","year":"2021","unstructured":"Lamot L, Miler M, Vukojevic R, Vidovic M, Lamot M, Trutin I, et al. The increased levels of fecal calprotectin in children with active enthesitis related arthritis and MRI signs of sacroiliitis: the results of a single center cross-sectional exploratory study in juvenile idiopathic arthritis patients. Front Med (Lausanne). 2021;8:650619.","journal-title":"Front Med (Lausanne)"},{"key":"3663_CR23","first-page":"2279","volume":"22","author":"H Mielants","year":"1995","unstructured":"Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol. 1995;22:2279\u201384.","journal-title":"J Rheumatol"},{"key":"3663_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1136\/annrheumdis-2015-208025","volume":"75","author":"H Cypers","year":"2016","unstructured":"Cypers H, Varkas G, Beeckman S, Debusschere K, Vogl T, Roth J, et al. Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. Ann Rheum Dis. 2016;75:1357\u201362.","journal-title":"Ann Rheum Dis"},{"key":"3663_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3899\/jrheum.161216","volume":"45","author":"U Kopylov","year":"2018","unstructured":"Kopylov U, Starr M, Watts C, Dionne S, Girardin M, Seidman EG. Detection of Crohn disease in patients with spondyloarthropathy: the SpACE Capsule Study. J Rheumatol. 2018;45:498\u2013505.","journal-title":"J Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03663-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03663-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:03:25Z","timestamp":1761080605000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03663-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3663"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03663-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was granted by the Regional Ethics Committee in Lund, Sweden (Dnr:2015\/436). Oral and written informed consent was acquired before entry into the study, which was performed in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JKW: Speakers bureau: AbbVie, Amgen; Grant\/research support: AbbVie, Amgen, Eli Lilly, Novartis, Pfizer. EM: Speakers bureau: AbbVie, Novartis. JS: None declared. KA: None declared. JM: Speakers bureau: AbbVie, Amgen, Bayer, Biogen, BMS, Ferring, Galapagos, ITH, Janssen, Lument, MSD, Otsuka, Pfizer, Sandoz, Takeda, Tillotts, UCB; Grant\/research support: AbbVie, BMS, Calpro AS, Carbiotix, Ferring, Fresenius Kabi, Pfizer, Svar Life Science, Takeda. FI: None declared. MG: Speakers bureau: AbbVie, UCB. TO: Consultant: Eli Lilly, MSD. EL: None declared.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}